Protara Therapeutics Inc Financials

TARA

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Weak

3/9

Protara Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.80x

For every $1 of reported earnings, Protara Therapeutics Inc generates $0.80 in operating cash flow (-$35.8M OCF vs -$44.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

This page shows Protara Therapeutics Inc (TARA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

-$48.8M

YoY-12.8%

Protara Therapeutics Inc's EBITDA was -$48.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.8% from the prior year.

Free Cash Flow

-$35.9M

YoY+4.6%

Protara Therapeutics Inc generated -$35.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 4.6% from the prior year.

Net Income

-$44.6M

YoY-10.3%

Protara Therapeutics Inc reported -$44.6M in net income in fiscal year 2024. This represents a decrease of 10.3% from the prior year.

EPS (Diluted)

$-2.17

Protara Therapeutics Inc earned $-2.17 per diluted share (EPS) in fiscal year 2024. This represents an increase of 39.2% from the prior year.

Cash & Debt

$162.8M

YoY+311.3%

5Y CAGR+210.5%

10Y CAGR+9.0%

Protara Therapeutics Inc held $162.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

35M

Protara Therapeutics Inc had 35M shares outstanding in fiscal year 2024. This represents an increase of 208.4% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$31.7M

YoY+26.9%

5Y CAGR+52.2%

10Y CAGR+17.3%

Protara Therapeutics Inc invested $31.7M in research and development in fiscal year 2024. This represents an increase of 26.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$63K

YoY+40.0%

5Y CAGR-33.2%

10Y CAGR+2.1%

Protara Therapeutics Inc invested $63K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 40.0% from the prior year.

TARA Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$31.7M+26.9%	$25.0M+48.7%	$16.8M-20.3%	$21.1M+76.0%	$12.0M+209.0%	$3.9M
SG&A Expenses	$17.4M-6.3%	$18.6M-10.2%	$20.7M-21.5%	$26.4M+17.5%	$22.5M+468.4%	$4.0M
Operating Income	-$49.2M-12.7%	-$43.6M+35.0%	-$67.1M-41.2%	-$47.5M-37.9%	-$34.4M-339.9%	-$7.8M
Interest Expense	N/A	N/A	N/A	$0-100.0%	$34K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$44.6M-10.3%	-$40.4M+38.7%	-$66.0M-39.6%	-$47.3M-39.1%	-$34.0M-333.9%	-$7.8M
EPS (Diluted)	$-2.17	$-3.57+39.1%	$-5.86-39.2%	$-4.21	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$9.6M+18.8%	$8.1M	N/A	$6.2M	N/A	$3.5M	N/A	$4.1M
SG&A Expenses	$5.2M+21.3%	$4.3M	N/A	$4.5M	N/A	$4.5M	N/A	$6.7M
Operating Income	-$14.8M-19.7%	-$12.3M	N/A	-$10.7M	N/A	-$8.0M	N/A	-$10.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$53K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$13.3M-18.2%	-$11.2M	N/A	-$9.9M	N/A	-$7.7M	N/A	-$10.8M
EPS (Diluted)	$-0.31+38.0%	$-0.50	N/A	$-0.87	N/A	$-0.68	N/A	$-0.96

TARA Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$181.5M+129.8%	$79.0M-30.3%	$113.3M-34.4%	$172.6M-15.0%	$203.2M+16511.4%	$1.2M
Current Assets	$172.2M+150.6%	$68.7M-20.2%	$86.1M-7.5%	$93.1M-45.0%	$169.4M+22077.4%	$764K
Cash & Equivalents	$162.8M+311.3%	$39.6M+64.1%	$24.1M-32.5%	$35.7M-78.8%	$168.6M+29793.3%	$564K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$29.5M0.0%	$29.5M+0.1%	$29.5M
Total Liabilities	$14.3M+34.7%	$10.6M-5.1%	$11.2M+4.9%	$10.7M+172.9%	$3.9M+16.8%	$3.4M
Current Liabilities	$11.0M+78.3%	$6.1M+7.1%	$5.7M+33.6%	$4.3M+47.4%	$2.9M-13.0%	$3.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$167.1M+144.6%	$68.3M-33.1%	$102.1M-37.0%	$161.9M-18.7%	$199.2M+9462.9%	-$2.1M
Retained Earnings	-$245.0M-22.3%	-$200.4M-25.3%	-$160.0M-70.2%	-$94.0M-101.1%	-$46.8M-265.8%	-$12.8M

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Total Assets	$144.6M-20.3%	$181.5M+129.8%	$79.0M-10.8%	$88.5M-21.9%	$113.3M-23.8%	$148.6M-13.9%	$172.6M-4.5%	$180.7M
Current Assets	$135.6M-21.2%	$172.2M+150.6%	$68.7M-11.7%	$77.8M-9.7%	$86.1M-12.7%	$98.7M+6.0%	$93.1M-2.7%	$95.7M
Cash & Equivalents	$12.6M-92.3%	$162.8M+311.3%	$39.6M+17.2%	$33.8M+40.0%	$24.1M-49.2%	$47.5M+33.0%	$35.7M-12.3%	$40.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	$29.5M0.0%	$29.5M0.0%	$29.5M
Total Liabilities	$12.3M-13.8%	$14.3M+34.7%	$10.6M-7.6%	$11.5M+2.7%	$11.2M+19.1%	$9.4M-11.9%	$10.7M+3.8%	$10.3M
Current Liabilities	$9.9M-9.6%	$11.0M+78.3%	$6.1M-9.2%	$6.8M+18.0%	$5.7M+54.7%	$3.7M-13.7%	$4.3M+16.5%	$3.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$132.3M-20.8%	$167.1M+144.6%	$68.3M-11.2%	$77.0M-24.6%	$102.1M-26.7%	$139.2M-14.0%	$161.9M-5.0%	$170.4M
Retained Earnings	-$285.1M-16.4%	-$245.0M-22.3%	-$200.4M-5.4%	-$190.2M-18.9%	-$160.0M-32.2%	-$121.0M-28.7%	-$94.0M-12.2%	-$83.8M

TARA Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$35.8M+4.7%	-$37.6M-42.0%	-$26.5M+23.3%	-$34.5M-47.4%	-$23.4M-367.1%	-$5.0M
Capital Expenditures	$63K+40.0%	$45K-62.5%	$120K-79.9%	$596K-32.6%	$884K+86.1%	$475K
Free Cash Flow	-$35.9M+4.6%	-$37.6M-41.5%	-$26.6M+24.3%	-$35.1M-44.5%	-$24.3M-342.8%	-$5.5M
Investing Cash Flow	$19.2M-63.9%	$53.1M+255.2%	$14.9M+115.2%	-$98.2M-3563.6%	$2.8M+696.8%	-$475K
Financing Cash Flow	$139.9M+153797.8%	-$91K-1.1%	-$90K+60.5%	-$228K-100.1%	$189.4M+37780.2%	$500K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$91K+1.1%	$90K-60.5%	$228K	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Operating Cash Flow	-$12.5M-33.8%	-$9.3M-7.0%	-$8.7M-32.6%	-$6.6M-30.5%	-$5.0M+6.0%	-$5.3M+22.6%	-$6.9M-11.4%	-$6.2M
Capital Expenditures	$4K	$0	$0-100.0%	$37K+516.7%	$6K-92.8%	$83K+88.6%	$44K+168.8%	-$64K
Free Cash Flow	-$12.5M-33.8%	-$9.3M-7.0%	-$8.7M-31.9%	-$6.6M-31.1%	-$5.0M+7.3%	-$5.4M+21.9%	-$7.0M-10.9%	-$6.3M
Investing Cash Flow	-$6.5M-128.9%	$22.5M+55.0%	$14.5M+127.6%	$6.4M+134.8%	-$18.3M-196.3%	$19.0M+908.4%	$1.9M+1665.4%	$107K
Financing Cash Flow	$13K-100.0%	$97.8M	$0+100.0%	-$27K	$0+100.0%	-$18K	$0	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$76K	$0-100.0%	$27K	$0-100.0%	$18K	$0	$0

TARA Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-24.6%+26.6pp	-51.2%+7.0pp	-58.2%-30.8pp	-27.4%-10.7pp	-16.7%+623.5pp	-640.2%
Current Ratio	15.71+4.5	11.17-3.8	15.01-6.7	21.66-36.5	58.13+57.9	0.23
Debt-to-Equity	0.09-0.1	0.16+0.0	0.11+0.0	0.07+0.0	0.02+1.6	-1.57
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-9.2%+2.7pp	-11.9%	N/A	-11.2%	N/A	-5.2%	N/A	-6.0%
Current Ratio	13.69-2.0	15.71+4.5	11.17-0.3	11.49-3.5	15.01-11.6	26.59+4.9	21.66-4.3	25.95
Debt-to-Equity	0.090.0	0.09-0.1	0.160.0	0.15+0.0	0.11+0.0	0.070.0	0.070.0	0.06
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Io Biotech, Inc. IOBT

$25.6M

Inhibikase Therapeutics Inc IKT

$198.9M

Kala Pharmaceuticals Inc KALA

$331.1M

Equillium EQ

$97.4M

Biomea Fusion, Inc. BMEA

$88.4M

Frequently Asked Questions

Is Protara Therapeutics Inc profitable?

No, Protara Therapeutics Inc (TARA) reported a net income of -$44.6M in fiscal year 2024.

What is Protara Therapeutics Inc's earnings per share (EPS)?

Protara Therapeutics Inc (TARA) reported diluted earnings per share of $-2.17 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Protara Therapeutics Inc's EBITDA?

Protara Therapeutics Inc (TARA) had EBITDA of -$48.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Protara Therapeutics Inc's free cash flow?

Protara Therapeutics Inc (TARA) generated -$35.9M in free cash flow during fiscal year 2024. This represents a 4.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Protara Therapeutics Inc's operating cash flow?

Protara Therapeutics Inc (TARA) generated -$35.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Protara Therapeutics Inc's total assets?

Protara Therapeutics Inc (TARA) had $181.5M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Protara Therapeutics Inc's capital expenditures?

Protara Therapeutics Inc (TARA) invested $63K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Protara Therapeutics Inc spend on research and development?

Protara Therapeutics Inc (TARA) invested $31.7M in research and development during fiscal year 2024.

How many shares does Protara Therapeutics Inc have outstanding?

Protara Therapeutics Inc (TARA) had 35M shares outstanding as of fiscal year 2024.

What is Protara Therapeutics Inc's current ratio?

Protara Therapeutics Inc (TARA) had a current ratio of 15.71 as of fiscal year 2024, which is generally considered healthy.

What is Protara Therapeutics Inc's debt-to-equity ratio?

Protara Therapeutics Inc (TARA) had a debt-to-equity ratio of 0.09 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Protara Therapeutics Inc's return on assets (ROA)?

Protara Therapeutics Inc (TARA) had a return on assets of -24.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Protara Therapeutics Inc's cash runway?

Based on fiscal year 2024 data, Protara Therapeutics Inc (TARA) had $162.8M in cash against an annual operating cash burn of $35.8M. This gives an estimated cash runway of approximately 55 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Protara Therapeutics Inc's Piotroski F-Score?

Protara Therapeutics Inc (TARA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Protara Therapeutics Inc's earnings high quality?

Protara Therapeutics Inc (TARA) has an earnings quality ratio of 0.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.